HALO logo
ATH
Alterity Therapeutics Ltd.

ATH · Alterity Therapeutics Ltd.

0.22

AUD
0.00 (0.00%)
18/11/2026 04:10:15 PM
+1
Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

AU$49.27M

PE

0.00

EV/EBITDA

N/A

DIV Yield

0%

Franking

0%

MQV Rating

5Very Weak

As at 18/11/2026 04:10:15 PM

Price StockChart

Description

Alterity Therapeutics Ltd. engages in the business of research and development of therapeutic drugs designed to treat neurodegenerative diseases, focusing on Parkinsonian and other movement disorders. Its lead candidate, ATH434, is an oral small molecule drug designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

  • All-Companies
  • All-Consensus
  • Big Candle
  • GROWTH AUS
  • HALO Consensus Value
  • HALO Ords
  • Near Support

Key Fundamentals

EPS 3 yr Growth

-60.90%

EBITDA Margin

N/A

Operating Cashflow

-$23m

Free Cash Flow Return

-52.80%

ROIC

-54.80%

Interest Coverage

N/A

Quick Ratio

14.50

Performance

52 weeks range

Low 0.2 - 0.79

Trade Value (12mth)

AU$23,445.00

1 week

-20.37%

1 month

-20.37%

YTD

-52.22%

1 year

-52.22%

All time high

75.00

Additional Data

Shares Outstanding (Fully Diluted)

218m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.02

Consensus score

Lock Icon/10

Recommendation

Buy

Target price

Lock Icon

Deviation

Lock Icon

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Strong

Value

Lock Icon

Consensus

Lock Icon

Yield

Lock Icon

News & Announcements

DateEvent
12 November 26ASXD
30 October 26ASXD
23 October 26ASXD
23 October 26ASXD
23 October 26ASXD

Key Stakeholders

NameTitle
David A. StamlerIndividual
Geoffrey Paul KemplerIndividual
Peter Ashley MarksIndividual
Brian Derek MeltzerIndividual
Lawrence Bernard GozlanIndividual

See beyond the curve.

One solution for research, investing and model portfolio management.
Want to learn more?Frequently asked questions.
1
What is the current share price of Alterity Therapeutics Ltd. (ATH:ASX)?
Halo FAQ
The current share price of Alterity Therapeutics Ltd. (ATH:ASX) is AUD$0.22.
2
What is the 52-week high share price for Alterity Therapeutics Ltd. (ATH:ASX)?
Halo FAQ
The 52-week high share price for Alterity Therapeutics Ltd. (ATH:ASX) is AUD$0.79.
3
What is the 52-week low share price for Alterity Therapeutics Ltd. (ATH:ASX)?
Halo FAQ
The 52-week low share price for Alterity Therapeutics Ltd. (ATH:ASX) is AUD$0.20.
4
What is the dividend yield for Alterity Therapeutics Ltd. (ATH:ASX)?
Halo FAQ
Alterity Therapeutics Ltd. (ATH:ASX) does not pay a dividend.
5
What was Alterity Therapeutics Ltd. (ATH:ASX) last dividend payment?
Halo FAQ
Alterity Therapeutics Ltd. (ATH:ASX) does not pay a dividend.
6
What is the franking level for Alterity Therapeutics Ltd. (ATH:ASX)?
Halo FAQ
Alterity Therapeutics Ltd. (ATH:ASX) has a franking level of 0.00%.
7
In which sector is Alterity Therapeutics Ltd. (ATH:ASX) classified?
Halo FAQ
Alterity Therapeutics Ltd. (ATH:ASX) is classified in the Healthcare.